

STATUTORY INSTRUMENTS

2019 No. 775

**The Human Medicines (Amendment
etc.) (EU Exit) Regulations 2019**

PART 2

Amendment of Part 1 (General)

Amendment of regulation 5 (classification of medicinal products)

7.—(1) Regulation 5 is amended as follows.

[^{F1}(2) In paragraph (1)(b), before “a product that” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(3) In paragraph (2)—

^{F2}(a)

[^{F3}(b) in sub-paragraph (d), before “an Article 126a” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(4) In paragraph (3)—

[^{F4}(a) in sub-paragraph (b), before “a medicinal product” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”;]

^{F5}(b)

(5) In paragraph (4), [^{F6}in sub-paragraph (b), before “an Article” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(6) In paragraph (5)—

[^{F7}(a) in sub-paragraph (b), before “a product that” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”; and]

^{F8}(b)

Textual Amendments

- F1** Reg. 7(2) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(a)**
- F2** Reg. 7(3)(a) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(b)(i)**
- F3** Reg. 7(3)(b) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(b)(ii)**
- F4** Reg. 7(4)(a) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(c)(i)**
- F5** Reg. 7(4)(b) omitted (31.12.2020) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(c)(ii)**

Changes to legislation: *There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 7. (See end of Document for details)*

- F6** Words in reg. 7(5) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(d)**
- F7** Reg. 7(6)(a) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(e)(i)**
- F8** Reg. 7(6)(b) omitted (31.12.2020 immediately before IP completion day) by virtue of [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, **Sch. 2 para. 4(e)(ii)**

Commencement Information

- I1** Reg. 7 in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1, Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 7.